HealthcareLtd Dirección

Dirección controles de criterios 4/4

El CEO de HealthcareLtd es Zhang Gen Ni, nombrado en Oct 2012, tiene una permanencia de 12.08 años. posee directamente un 33.97% de las acciones de la empresa, con un valor de CN¥1.31B. La antigüedad media del equipo directivo y de la junta directiva es de 12.1 años y 10.3 años, respectivamente.

Información clave

Zhang Gen Ni

Chief Executive Officer (CEO)

CN¥804.8k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	12.1yrs
Participación del CEO	34.0%
Permanencia media de la dirección	12.1yrs
Promedio de permanencia en la Junta Directiva	10.3yrs

Actualizaciones recientes de la dirección

Recent updates

Market Participants Recognise Healthcare Co.,Ltd.'s (SHSE:603313) Earnings

Sep 26

HealthcareLtd's (SHSE:603313) Profits Appear To Have Quality Issues

Sep 06

CEO

Zhang Gen Ni (49 yo)

12.1yrs

Permanencia

CN¥804,800

Compensación

Mr. Zhang Gen Ni is Chairman of the Board & President of Healthcare Co., Ltd. since October 29, 2012. He was Chairman of the Board, General Manager and Director of Development Center of Healthcare Co., Ltd...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Zhang Gen Ni	Chairman of the Board & President	12.1yrs	CN¥804.80k	33.97% CN¥ 1.3b
Xiao Hong Wu	VP & Director	12.1yrs	CN¥441.40k	0.0053% CN¥ 205.3k
Hong Jian Zhang	VP & Director	12.1yrs	CN¥710.30k	0.0053% CN¥ 205.3k
Hailong Zhang	Accounting Supervisor	no data	sin datos	sin datos

12.1yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 603313 es experimentado (12.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Zhang Gen Ni	Chairman of the Board & President	12.1yrs	CN¥804.80k	33.97% CN¥ 1.3b
Xiao Hong Wu	VP & Director	12.1yrs	CN¥441.40k	0.0053% CN¥ 205.3k
Hong Jian Zhang	VP & Director	12.1yrs	CN¥710.30k	0.0053% CN¥ 205.3k
Jian Long Ji	Director	8.5yrs	CN¥474.10k	0.0053% CN¥ 205.3k
Tao Lin	Employee Supervisor	12.1yrs	sin datos	sin datos
Hua Wei	Member of Supervisory Board	12.1yrs	sin datos	sin datos
Chang Ling Zhu	Independent Director	5.6yrs	CN¥80.00k	sin datos
Baiming Xu	Independent Director	5.6yrs	CN¥80.00k	sin datos
Zaifa Cai	Independent Director	5.6yrs	CN¥80.00k	sin datos
Jian Sun	Chairman of the Supervisory Board	7.9yrs	sin datos	sin datos

10.3yrs

Permanencia media

52yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 603313 son experimentados ( 10.3 años antigüedad media).

HealthcareLtd Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Healthcare Co.,Ltd., Annual General Meeting, May 17, 2024

Healthcare Co.,Ltd., Annual General Meeting, May 17, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New minor risk - Financial position

Healthcare Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 18%

Market Participants Recognise Healthcare Co.,Ltd.'s (SHSE:603313) Earnings

Price target decreased by 60% to CN¥5.30

HealthcareLtd's (SHSE:603313) Profits Appear To Have Quality Issues

Second quarter 2024 earnings released: EPS: CN¥0.065 (vs CN¥0.19 in 2Q 2023)

Now 22% overvalued

Healthcare Co.,Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Healthcare Co.,Ltd., Annual General Meeting, May 17, 2024

Healthcare Co.,Ltd., Annual General Meeting, May 17, 2024

Healthcare Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Shareholder dilution

Healthcare Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

New major risk - Financial position

Third quarter 2023 earnings released: EPS: CN¥0.031 (vs CN¥0.03 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.11 in 2Q 2022)

Now 20% undervalued

Price target decreased by 10% to CN¥12.68

First quarter 2023 earnings released: EPS: CN¥0.03 (vs CN¥0.06 in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.03 (vs CN¥0.59 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.12 loss in 2Q 2021)

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to CN¥15.00

Less than half of directors are independent

Third quarter 2021 earnings released: CN¥0.59 loss per share (vs CN¥0.42 profit in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target decreased to CN¥29.93

Second quarter 2021 earnings released: CN¥0.12 loss per share (vs CN¥0.17 profit in 2Q 2020)

Investor sentiment deteriorated over the past week

Price target decreased to CN¥28.03

Price target increased to CN¥52.73

Full year 2020 earnings released: EPS CN¥1.11 (vs CN¥1.18 in FY 2019)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day high: CN¥43.05

New 90-day high: CN¥39.17

Investor sentiment improved over the past week

Market bids up stock over the past week

New 90-day high: CN¥36.87

Price target raised to CN¥46.61

Analysts update estimates

Healthcare Co., Ltd. to Report Q3, 2020 Results on Oct 31, 2020

Third quarter earnings released

Price target raised to CN¥36.16

Earnings released

New 90-day high - CN¥29.33

New 90-day high - CN¥26.83

Healthcare Co., Ltd. to Report First Half, 2020 Results on Aug 29, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad